Search

Your search keyword '"Sznol M"' showing total 386 results
Start Over Author "Sznol M"
386 results on '"Sznol M"'

1. A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma

Author

Godshalk, SE, Paranjape, T, Nallur, S, Speed, W, Chan, E, Molinaro, AM, Bacchiocchi, A, Hoyt, K, Tworkoski, K, Stern, DF, Sznol, M, Ariyan, S, Lazova, R, Halaban, R, Kidd, KK, Weidhaas, JB, and Slack, FJ

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Cancer, Biotechnology, Genetics, 2.1 Biological and endogenous factors, Aetiology, 3' Untranslated Regions, Case-Control Studies, Humans, Melanoma, MicroRNAs, Oncogenes, Protein Biosynthesis, Proto-Oncogene Proteins c-kit, RNA, Messenger, Risk, Skin Neoplasms, melanoma, acral, microRNA, cancer risk, miR-221, KIT, Clinical Sciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

MicroRNAs (miRNAs) are small ∼22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3' untranslated region (3' UTRs) of target gene messenger RNAs (mRNA). Recently, mutations have been identified in both miRNAs and target genes that disrupt regulatory relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has recently been shown to be upregulated in some melanomas, and is also a target of the miRNA miR-221. Here, we describe a genetic variant in the 3' UTR of the KIT oncogene that correlates with a greater than fourfold increased risk of acral melanoma. This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression of the KIT oncogene. Consistent with the hypothesis that this is a functional variant, KIT mRNA and protein levels are both increased in the majority of samples harboring the KIT variant. This work identifies a novel genetic marker for increased heritable risk of melanoma.

Published
2011

3. 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

Author

Diab, A., primary, Gogas, H.J., additional, Sandhu, S.K., additional, Long, G.V., additional, Ascierto, P.A., additional, Larkin, J., additional, Sznol, M., additional, Franke, F.A., additional, Ciuleanu, T-E., additional, Muñoz Couselo, E., additional, Perfetti, A., additional, Lebbe, C., additional, Meier, F., additional, Curti, B., additional, Rojas, C., additional, Yang, H., additional, Zhou, M., additional, Ravimohan, S., additional, Tagliaferri, M.A., additional, and Khushanlani, N., additional

Published
2022
Full Text
View/download PDF

4. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Author

Kim, TW, Burris, HA, Luken, MJDM, Pishvaian, MJ, Bang, Y-J, Gordon, M, Awada, A, Camidge, DR, Hodi, FS, McArthur, GA, Miller, WH, Cervantes, A, Chow, LQ, Lesokhin, AM, Rutten, A, Sznol, M, Rishipathak, D, Chen, S-C, Stefanich, E, Pourmohamad, T, Anderson, M, Kim, J, Huseni, M, Rhee, I, Siu, LL, Kim, TW, Burris, HA, Luken, MJDM, Pishvaian, MJ, Bang, Y-J, Gordon, M, Awada, A, Camidge, DR, Hodi, FS, McArthur, GA, Miller, WH, Cervantes, A, Chow, LQ, Lesokhin, AM, Rutten, A, Sznol, M, Rishipathak, D, Chen, S-C, Stefanich, E, Pourmohamad, T, Anderson, M, Kim, J, Huseni, M, Rhee, I, and Siu, LL

Abstract

PURPOSE: OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody. PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer. RESULTS: MOXR0916 was well tolerated with no dose-limiting toxicities observed. An MTD was not reached. Most patients (95%) experienced at least one adverse event (AE); 56% of AEs, mostly grade 1-2, were related to MOXR0916. Most common treatment-related AEs included fatigue (17%), diarrhea (8%), myalgia (7%), nausea (6%), decreased appetite (6%), and infusion-related reaction (5%). Pharmacokinetic (PK) parameters were dose proportional between 80 and 1,200 mg and supported Q3W administration. The recommended expansion dose based on PK and OX40 receptor saturation was 300 mg Q3W. Immune activation and upregulation of PD-L1 was observed in a subset of paired tumor biopsies. One renal cell carcinoma patient experienced a confirmed partial response. Overall, 33% of patients achieved stable disease. CONCLUSIONS: Although objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists.

Published
2022

5. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Author

Long, G.V., primary, Arance, A., additional, Mortier, L., additional, Lorigan, P., additional, Blank, C., additional, Mohr, P., additional, Schachter, J., additional, Grob, J.-J., additional, Lotem, M., additional, Middleton, M.R., additional, Neyns, B., additional, Steven, N., additional, Ribas, A., additional, Walpole, E., additional, Carlino, M.S., additional, Lebbe, C., additional, Sznol, M., additional, Jensen, E., additional, Leiby, M.A., additional, Ibrahim, N., additional, and Robert, C., additional

Published
2022
Full Text
View/download PDF

7. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer.

Author

Munneke B., Brody J.D., Hernandez-Aya L., Bonomi P., Goldman J.W., Berim L., Renouf D.J., Goodwin R.A., Ho P.Y., Hsieh J., McCaffery I., Kwei L., Willingham S.B., Miller R.A., Fong L., Hotson A., Powderly J.D., Sznol M., Heist R.S., Choueiri T.K., George S., Hughes B.G.M., Hellmann M.D., Shepard D.R., Rini B.I., Kummar S., Weise A.M., Riese M.J., Markman B., Emens L.A., Mahadevan D., Luke J.J., Laport G., Munneke B., Brody J.D., Hernandez-Aya L., Bonomi P., Goldman J.W., Berim L., Renouf D.J., Goodwin R.A., Ho P.Y., Hsieh J., McCaffery I., Kwei L., Willingham S.B., Miller R.A., Fong L., Hotson A., Powderly J.D., Sznol M., Heist R.S., Choueiri T.K., George S., Hughes B.G.M., Hellmann M.D., Shepard D.R., Rini B.I., Kummar S., Weise A.M., Riese M.J., Markman B., Emens L.A., Mahadevan D., Luke J.J., and Laport G.

Abstract

Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8 + T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. SIGNIFICANCE: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti-PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies.Copyright © 2019 American Association for Cancer Research.

Published
2020

10. Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444.

Author

Kwei L., Willingham S., Laport G., Miller R., Fong L., Powderly J., Luke J., Hotson D., Sznol M., George S., Choueiri T., Rini B., Hellmann M., Kummar S., Hernandez-Aya L., Mahadevan D., Hughes B., Markman B., Riese M., Brody J., Renouf D., Heist R., Goodwin R., Weise A., Emens L., Kwei L., Willingham S., Laport G., Miller R., Fong L., Powderly J., Luke J., Hotson D., Sznol M., George S., Choueiri T., Rini B., Hellmann M., Kummar S., Hernandez-Aya L., Mahadevan D., Hughes B., Markman B., Riese M., Brody J., Renouf D., Heist R., Goodwin R., Weise A., and Emens L.

Abstract

Background Adenosine plays a role in blocking the function of immune cells through binding to the A2AR. CPI-444 is an oral A2AR antagonist that has been evaluated in Phase 1 trials in advanced cancer. Methods This Phase 1b trial was conducted at 30 centers. RCC patients (pts) with progressive disease were randomized to receive either CPI-444, 100 mg po bid monotherapy or CPI-444 in combination with atezolizumab 840 mg IV every 2 weeks and treated until progression or unacceptable toxicity. Endpoints included safety, tumor response (RR), progression free survival and overall survival (OS). Peripheral blood and tumor biopsies were obtained at baseline and on-treatment and evaluated for lymphocyte subsets and gene expression of A2AR using Nanostring. A2AR signaling was assessed by measurement of inhibition of pCREB. Results Results: 68 pts enrolled (N=33 monotherapy, N=35 combination); median prior therapies was 3 (range 1-5) including TKI, 84%; anti-PD(L)1 (IO), 72%; median time since last IO was 3.1 and 1.7 months for monotherapy and combination, respectively. Median treatment duration was 4.6 months. CPI-444 was well-tolerated with no Gr3/4 toxicity in monotherapy; 7 pts had reversible Gr3 toxicity in combination. CPI-444 blocked A2AR signaling based on inhibition of phosphorylation of CREB in blood lymphocytes. A2AR mRNA was measured in 31 pre-treatment RCC tumor biopsies and compared to other cancers (36 lung; 12 bladder; 5 colon; 8 prostate, 9 melanoma and 20 triple negative breast). RCC showed increase in A2AR expression compared to lung (p<0.01) and the other tumors (p<0.001). Objective clinical responses were observed in 8% of pts; another 21% had reduction of tumor not meeting criteria for response. Responses were seen in both monotherapy and combination arms and in pts who failed prior IO agents. 40% and 58% of pts experienced disease control (DC) for > 3 months (confirmed scans) in monotherapy and combination, respectively, including in pts resistant to pri

Published
2019

15. P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Author

Papadimitrakopoulou, V., primary, Tannir, N., additional, Bernatchez, C., additional, Haymaker, C., additional, Bentebibel, S., additional, Curti, B., additional, Wong, M., additional, Gergel, I., additional, Tagliaferri, M., additional, Zalevsky, J., additional, Hoch, U., additional, Aung, S., additional, Imperiale, M., additional, Cho, D., additional, Tykodi, S., additional, Puzanov, I., additional, Kluger, H., additional, Hurwitz, M., additional, Hwu, P., additional, Sznol, M., additional, and Diab, A., additional

Published
2017
Full Text
View/download PDF

16. Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulation.

Author

Miller R., Willingham S., Laport G., McCaffery I., Lee J., Hotson A., Powderly J., Emens L., Forde P., Hellman M., Fong L., Markman B., Hughes B., Goldman J., Sznol M., Mahadevan D., Kummar S., Brody J., Bonomi P., Luke J., Riese M., Owonikoko T., Loi S., Wiese A., Doebele R., Gu C., Miller R., Willingham S., Laport G., McCaffery I., Lee J., Hotson A., Powderly J., Emens L., Forde P., Hellman M., Fong L., Markman B., Hughes B., Goldman J., Sznol M., Mahadevan D., Kummar S., Brody J., Bonomi P., Luke J., Riese M., Owonikoko T., Loi S., Wiese A., Doebele R., and Gu C.

Abstract

Background CPI-444, an A2AR antagonist, inhibits suppression of T cell function by adenosine and is active in multiple preclinical models. CPI-444 is being investigated as a single agent and in combination with atezolizumab in an ongoing Phase 1/1b clinical trial in patients with advanced cancers (NCT02655822). Biomarker investigations were conducted to explore immune modulation in serial tumor biopsies and peripheral blood as well associations between adenosine pathway genes and clinical activity. Methods Tumor biopsies and blood samples were analyzed in 80 patients with renal cell carcinoma (RCC: n=35), non-small cell lung cancer (NSCLC: n=26), triple negative breast cancer (TNBC: n=17), microsatellite instable colorectal cancer (MSI-CRC n=2) treated with CPI-444 100mg BID as single agent ('SA' n=18) or in combination with atezolizumab ('combo' n=62). Paired tumor biopsies were analyzed: gene expression profiles (Nanostring), CD8, PD-L1 and CD73 (IHC). T cell repertoires were examined by sequencing of the T cell receptor beta chain gene in PBMCs and tumors. Results Of 80 evaluable patients, 54 had progressed on prior anti-PD-(L) 1 therapy ('IO-refractory'), 26 were IO-naive. Most patients were PD-L1 negative in archival tumor (80% TNBC, 91% RCC, 69% NSCLC). Six objective responses were observed: 2 partial responses (PR) in RCC (1 SA and 1 combo); 2 PRs in NSCLC (both combo); 1 PR MSICRC (combo) and 1 PR in TNBC (combo). Notably, 3 PRs were observed in IO-refractory patients (1 RCC, 2 NSCLC) and 2 PRs were PD-L1 negative (1 RCC, 1 NSCLC). SA and combo treatment significantly increased CD8+ cell infiltration (mean 2-fold; 95%CI 1.18-2.91), T cell activation and interferongamma pathway gene expression in biopsies as well as T cell clone expansion in both tumor biopsies and periphery. Shared clonotypes expanded in matched post-dose PBMCs and tumor suggesting trafficking of T cells following CPI-444 treatment. This included IOrefractory and PD-L1-negative patients. Pat

Published
2017

17. PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

Author

Diab, A., primary, Hurwitz, M.E., additional, Tannir, N., additional, Bernatchez, C., additional, Haymaker, C., additional, Bentebibel, S.E., additional, Curti, B.D., additional, Wong, M.K.K., additional, Gergel, I., additional, Tagliaferri, M., additional, Zalevsky, J., additional, Hoch, U., additional, Aung, S., additional, Imperiale, M., additional, Cho, D., additional, Tykodi, S.S., additional, Puzanov, I., additional, Kluger, H., additional, Hwu, P., additional, and Sznol, M., additional

Published
2017
Full Text
View/download PDF

18. Abstracts from the 4th ImmunoTherapy of Cancer Conference

Author

Ženka, J., primary, Caisová, V., additional, Uher, O., additional, Nedbalová, P., additional, Kvardová, K., additional, Masáková, K., additional, Krejčová, G., additional, Paďouková, L., additional, Jochmanová, I., additional, Wolf, K. I., additional, Chmelař, J., additional, Kopecký, J., additional, Loumagne, L., additional, Mestadier, J., additional, D’agostino, S., additional, Rohaut, A., additional, Ruffin, Y., additional, Croize, V., additional, Lemaître, O., additional, Sidhu, S. S., additional, Althammer, S., additional, Steele, K., additional, Rebelatto, M., additional, Tan, T., additional, Wiestler, T., additional, Spitzmueller, A., additional, Korn, R., additional, Schmidt, G., additional, Higgs, B., additional, Li, X., additional, Shi, L., additional, Jin, X., additional, Ranade, K., additional, Koeck, S., additional, Amann, A., additional, Gamerith, G., additional, Zwierzina, M., additional, Lorenz, E., additional, Zwierzina, H., additional, Kern, J., additional, Riva, M., additional, Baert, T., additional, Coosemans, A., additional, Giovannoni, R., additional, Radaelli, E., additional, Gsell, W., additional, Himmelreich, U., additional, Van Ranst, M., additional, Xing, F., additional, Qian, W., additional, Dong, C., additional, Xu, X., additional, Guo, S., additional, Shi, Q., additional, Quandt, D., additional, Seliger, B., additional, Plett, C., additional, Amberger, D. C., additional, Rabe, A., additional, Deen, D., additional, Stankova, Z., additional, Hirn, A., additional, Vokac, Y., additional, Werner, J., additional, Krämer, D., additional, Rank, A., additional, Schmid, C., additional, Schmetzer, H., additional, Guerin, M., additional, Weiss, J. M., additional, Regnier, F., additional, Renault, G., additional, Vimeux, L., additional, Peranzoni, E., additional, Feuillet, V., additional, Thoreau, M., additional, Guilbert, T., additional, Trautmann, A., additional, Bercovici, N., additional, Doraneh-Gard, F., additional, Boeck, C. L., additional, Gunsilius, C., additional, Kugler, C., additional, Schmohl, J., additional, Kraemer, D., additional, Ismann, B., additional, Schmetzer, H. M., additional, Markota, A., additional, Ochs, C., additional, May, P., additional, Gottschlich, A., additional, Gosálvez, J. Suárez, additional, Karches, C., additional, Wenk, D., additional, Endres, S., additional, Kobold, S., additional, Hilmenyuk, T., additional, Klar, R., additional, Jaschinski, F., additional, Augustin, F., additional, Manzl, C., additional, Hoflehner, E., additional, Moser, P., additional, Zelger, B., additional, Köck, S., additional, Schäfer, G., additional, Öfner, D., additional, Maier, H., additional, Sopper, S., additional, Prado-Garcia, H., additional, Romero-Garcia, S., additional, Sandoval-Martínez, R., additional, Puerto-Aquino, A., additional, Lopez-Gonzalez, J., additional, Rumbo-Nava, U., additional, Van Hoylandt, A., additional, Busschaert, P., additional, Vergote, I., additional, Laengle, J., additional, Pilatova, K., additional, Budinska, E., additional, Bencsikova, B., additional, Sefr, R., additional, Nenutil, R., additional, Brychtova, V., additional, Fedorova, L., additional, Hanakova, B., additional, Zdrazilova-Dubska, L., additional, Allen, Chris, additional, Ku, Yuan-Chieh, additional, Tom, Warren, additional, Sun, Yongming, additional, Pankov, Alex, additional, Looney, Tim, additional, Hyland, Fiona, additional, Au-Young, Janice, additional, Mongan, Ann, additional, Becker, A., additional, Tan, J. B. L., additional, Chen, A., additional, Lawson, K., additional, Lindsey, E., additional, Powers, J. P., additional, Walters, M., additional, Schindler, U., additional, Young, S., additional, Jaen, J. C., additional, Yin, S., additional, Chen, Y., additional, Gullo, I., additional, Gonçalves, G., additional, Pinto, M. L., additional, Athelogou, M., additional, Almeida, G., additional, Huss, R., additional, Oliveira, C., additional, Carneiro, F., additional, Merz, C., additional, Sykora, J., additional, Hermann, K., additional, Hussong, R., additional, Richards, D. M., additional, Fricke, H., additional, Hill, O., additional, Gieffers, C., additional, Pinho, M. P., additional, Barbuto, J. A. M., additional, McArdle, S. E., additional, Foulds, G., additional, Vadakekolathu, J. N., additional, Abdel-Fatah, T. M. A., additional, Johnson, C., additional, Hood, S., additional, Moseley, P., additional, Rees, R. C., additional, Chan, S. Y. T., additional, Pockley, A. G., additional, Rutella, S., additional, Geppert, C., additional, Hartmann, A., additional, Kumar, K. Senthil, additional, Gokilavani, M., additional, Wang, S., additional, Redondo-Müller, M., additional, Heinonen, K., additional, Marschall, V., additional, Thiemann, M., additional, Zhang, L., additional, Mao, B., additional, Jin, Y., additional, Zhai, G., additional, Li, Z., additional, Wang, Z., additional, An, X., additional, Qiao, M., additional, Zhang, J., additional, Weber, J., additional, Kluger, H., additional, Halaban, R., additional, Sznol, M., additional, Roder, H., additional, Roder, J., additional, Grigorieva, J., additional, Asmellash, S., additional, Meyer, K., additional, Steingrimsson, A., additional, Blackmon, S., additional, Sullivan, R., additional, Sutanto, W., additional, Guenther, T., additional, Schuster, F., additional, Salih, H., additional, Babor, F., additional, Borkhardt, A., additional, Kim, Y., additional, Oh, I., additional, Park, C., additional, Ahn, S., additional, Na, K., additional, Song, S., additional, Choi, Y., additional, Poprach, A., additional, Lakomy, R., additional, Selingerova, I., additional, Demlova, R., additional, Kozakova, S., additional, Valik, D., additional, Petrakova, K., additional, Vyzula, R., additional, Aguilar-Cazares, D., additional, Galicia-Velasco, M., additional, Camacho-Mendoza, C., additional, Islas-Vazquez, L., additional, Chavez-Dominguez, R., additional, Gonzalez-Gonzalez, C., additional, Lopez-Gonzalez, J. S., additional, Yang, S., additional, Moynihan, K. D., additional, Noh, M., additional, Bekdemir, A., additional, Stellacci, F., additional, Irvine, D. J., additional, Volz, B., additional, Kapp, K., additional, Oswald, D., additional, Wittig, B., additional, Schmidt, M., additional, Kleef, R., additional, Bohdjalian, A., additional, McKee, D., additional, Moss, R. W., additional, Saeed, Mesha, additional, Zalba, Sara, additional, Debets, Reno, additional, ten Hagen, Timo L. M., additional, Javed, S., additional, Becher, J., additional, Koch-Nolte, F., additional, Haag, F., additional, Gordon, E. M., additional, Sankhala, K. K., additional, Stumpf, N., additional, Tseng, W., additional, Chawla, S. P., additional, Suárez, N. González, additional, Báez, G. Bergado, additional, Rodríguez, M. Cruz, additional, Pérez, A. Gutierrez, additional, García, L. Chao, additional, Fernández, D. Hernández, additional, Pous, J. Raymond, additional, Ramírez, B. Sánchez, additional, Jacoberger-Foissac, C., additional, Saliba, H., additional, Seguin, C., additional, Brion, A., additional, Frisch, B., additional, Fournel, S., additional, Heurtault, B., additional, Otterhaug, T., additional, Håkerud, M., additional, Nedberg, A., additional, Edwards, V., additional, Selbo, P., additional, Høgset, A., additional, Jaitly, T., additional, Dörrie, J., additional, Schaft, N., additional, Gross, S., additional, Schuler-Thurner, B., additional, Gupta, S., additional, Taher, L., additional, Schuler, G., additional, Vera, J., additional, Rataj, F., additional, Kraus, F., additional, Grassmann, S., additional, Chaloupka, M., additional, Lesch, S., additional, Heise, C., additional, Cadilha, B. M. Loureiro, additional, and Dorman, K., additional

Published
2017
Full Text
View/download PDF

19. Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Author

Long, G.V., primary, Robert, C., additional, Arance, A., additional, Blank, C., additional, Ribas, A., additional, Lorigan, P., additional, Mortier, L., additional, Schachter, J., additional, Middleton, M.R., additional, Neyns, B., additional, Sznol, M., additional, Zhou, H., additional, Ebbinghaus, S., additional, Ibrahim, N., additional, and Steven, N., additional

Published
2017
Full Text
View/download PDF

20. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

Author

Nanda, VGY, Peng, W, Hwu, P, Davies, MA, Ciliberto, G, Fattore, L, Malpicci, D, Aurisicchio, L, Ascierto, PA, Croce, CM, Mancini, R, Spranger, S, Gajewski, TF, Wang, Y, Ferrone, S, Vanpouille-Box, C, Wennerberg, E, Pilones, KA, Formenti, SC, Demaria, S, Tang, H, Fu, Y-X, Dummer, R, Puzanov, I, Tarhini, A, Chauvin, J-M, Pagliano, O, Fourcade, J, Sun, Z, Wang, H, Sanders, C, Kirkwood, JM, Chen, T-HT, Maurer, M, Korman, AJ, Zarour, HM, Stroncek, DF, Huber, V, Rivoltini, L, Thurin, M, Rau, T, Lugli, A, Pagès, F, Camarero, J, Sancho, A, Jommi, C, de Coaña, YP, Wolodarski, M, Yoshimoto, Y, Gentilcore, G, Poschke, I, Masucci, GV, Hansson, J, Kiessling, R, Scognamiglio, G, Sabbatino, F, Marino, FZ, Anniciello, AM, Cantile, M, Cerrone, M, Scala, S, D’alterio, C, Ianaro, A, Cirin, G, Liguori, G, Bott, G, Chapman, PB, Robert, C, Larkin, J, Haanen, JB, Ribas, A, Hogg, D, Hamid, O, Testori, A, Lorigan, P, Sosman, JA, Flaherty, KT, Yue, H, Coleman, S, Caro, I, Hauschild, A, McArthur, GA, Sznol, M, Callahan, MK, Kluger, H, Postow, MA, Gordan, R, Segal, NH, Rizvi, NA, Lesokhin, A, Atkins, MB, Burke, MM, Ralabate, A, Rivera, A, Kronenberg, SA, Agunwamba, B, Ruisi, M, Horak, C, Jiang, J, Wolchok, J, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stoyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Chang, I, Koralek, DO, Rooney, I, Yan, Y, Dréno, B, Sullivan, R, Patel, M, Hodi, S, Amaria, R, Boasberg, P, Wallin, J, He, X, Cha, E, Richie, N, Ballinger, M, Smith, DC, Bauer, TM, Wasser, JS, Luke, JJ, Balmanoukian, AS, Kaufman, DR, Zhao, Y, Maleski, J, Leopold, L, Gangadhar, TC, Long, GV, Michielin, O, VanderWalde, A, Andtbacka, RHI, Cebon, J, Fernandez, E, Malvehy, J, Olszanski, AJ, Gause, C, Chen, L, Chou, J, Stephen Hodi, F, Brady, B, Mortier, L, Hassel, JC, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Lebbé, C, Ny, L, Chacon, M, Queirolo, P, Loquai, C, Cheema, P, Berrocal, A, Eizmendi, KM, Bar-Sela, G, Hardy, H, Weber, JS, Grob, J-J, Marquez-Rodas, I, Schmidt, H, Briscoe, K, Baurain, J-F, Wolchok, JD, Pinto, R, De Summa, S, Garrisi, VM, Strippoli, S, Azzariti, A, Guida, G, Guida, M, Tommasi, S, Jacquelot, N, Enot, D, Flament, C, Pitt, JM, Vimond, N, Blattner, C, Yamazaki, T, Roberti, M-P, Vetizou, M, Daillere, R, Poirier-Colame, V, la Semeraro, M, Caignard, A, Slingluff, CL, Sallusto, F, Rusakiewicz, S, Weide, B, Marabelle, A, Kohrt, H, Dalle, S, Cavalcanti, A, Kroemer, G, Di Giacomo, AM, Wong, P, Yuan, J, Umansky, V, Eggermont, A, Zitvogel, L, Anna, P, Marco, T, Stefania, S, Francesco, M, Mariaelena, C, Gabriele, M, Antonio, AP, Franco, S, Roberti, MP, Enot, DP, Semeraro, M, Jégou, S, Flores, C, Kwon, BS, Anderson, AC, Borg, C, Aubin, F, Ayyoub, M, De Presbiteris, AL, Cordaro, FG, Camerlingo, R, Fratangelo, F, Mozzillo, N, Pirozzi, G, Patriarca, EJ, Caputo, E, Motti, ML, Falcon, R, Miceli, R, Capone, M, Madonna, G, Mallardo, D, Carrier, MV, Panza, E, De Cicco, P, Armogida, C, Ercolano, G, Botti, G, Cirino, G, Sandru, A, Blank, M, Balatoni, T, Olasz, J, Farkas, E, Szollar, A, Savolt, A, Godeny, M, Csuka, O, Horvath, S, Eles, K, Shoenfeld, Y, Kasler, M, Costantini, S, Capone, F, Moradi, F, Berglund, P, Leandersson, K, Linnskog, R, Andersson, T, Prasad, CP, Nigro, CL, Lattanzio, L, Proby, C, Syed, N, Occelli, M, Cauchi, C, Merlano, M, Harwood, C, Thompson, A, Crook, T, Bifulco, K, Ingangi, V, Minopoli, M, Ragone, C, Pessi, A, Mannavola, F, D’Oronzo, S, Felici, C, Tucci, M, Doronzo, A, Silvestris, F, Ferretta, A, Guida, S, Maida, I, Cocco, T, Passarelli, A, Quaresmini, D, Franzese, O, Palermo, B, Di Donna, C, Sperduti, I, Foddai, M, Stabile, H, Gismondi, A, Santoni, A, Nisticò, P, Sponghini, AP, Platini, F, Marra, E, Rondonotti, D, Alabiso, O, Fierro, MT, Savoia, P, Stratica, F, Quaglino, P, Di Monta, G, Corrado, C, Di Marzo, M, Ugo, M, Di Cecilia, ML, Nicola, M, Fusciello, C, Marra, A, Guarrasi, R, Baldi, C, Russo, R, Di Giulio, G, Faiola, V, Zeppa, P, Pepe, S, Gambale, E, Carella, C, Di Paolo, A, De Tursi, M, Marra, L, De Murtas, F, Sorrentino, V, Voinea, S, Panaitescu, E, Bolovan, M, Stanciu, A, Cinca, S, Botti, C, Aquino, G, Anniciello, A, Fortes, C, Mastroeni, S, Caggiati, A, Passarelli, F, Zappalà, A, Capuano, M, Bono, R, Nudo, M, Marino, C, Michelozzi, P, De Biasio, V, Battarra, VC, Formenti, S, Ascierto, ML, McMiller, TL, Berger, AE, Danilova, L, Anders, RA, Netto, GJ, Xu, H, Pritchard, TS, Fan, J, Cheadle, C, Cope, L, Drake, CG, Pardoll, DM, Taube, JM, Topalian, SL, Gnjatic, S, Nataraj, S, Imai, N, Rahman, A, Jungbluth, AA, Pan, L, Venhaus, R, Park, A, Lehmann, FF, Lendvai, N, Cohen, AD, Cho, HJ, Daniel, S, Hirsh, V, Nanda, VGY, Peng, W, Hwu, P, Davies, MA, Ciliberto, G, Fattore, L, Malpicci, D, Aurisicchio, L, Ascierto, PA, Croce, CM, Mancini, R, Spranger, S, Gajewski, TF, Wang, Y, Ferrone, S, Vanpouille-Box, C, Wennerberg, E, Pilones, KA, Formenti, SC, Demaria, S, Tang, H, Fu, Y-X, Dummer, R, Puzanov, I, Tarhini, A, Chauvin, J-M, Pagliano, O, Fourcade, J, Sun, Z, Wang, H, Sanders, C, Kirkwood, JM, Chen, T-HT, Maurer, M, Korman, AJ, Zarour, HM, Stroncek, DF, Huber, V, Rivoltini, L, Thurin, M, Rau, T, Lugli, A, Pagès, F, Camarero, J, Sancho, A, Jommi, C, de Coaña, YP, Wolodarski, M, Yoshimoto, Y, Gentilcore, G, Poschke, I, Masucci, GV, Hansson, J, Kiessling, R, Scognamiglio, G, Sabbatino, F, Marino, FZ, Anniciello, AM, Cantile, M, Cerrone, M, Scala, S, D’alterio, C, Ianaro, A, Cirin, G, Liguori, G, Bott, G, Chapman, PB, Robert, C, Larkin, J, Haanen, JB, Ribas, A, Hogg, D, Hamid, O, Testori, A, Lorigan, P, Sosman, JA, Flaherty, KT, Yue, H, Coleman, S, Caro, I, Hauschild, A, McArthur, GA, Sznol, M, Callahan, MK, Kluger, H, Postow, MA, Gordan, R, Segal, NH, Rizvi, NA, Lesokhin, A, Atkins, MB, Burke, MM, Ralabate, A, Rivera, A, Kronenberg, SA, Agunwamba, B, Ruisi, M, Horak, C, Jiang, J, Wolchok, J, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stoyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Chang, I, Koralek, DO, Rooney, I, Yan, Y, Dréno, B, Sullivan, R, Patel, M, Hodi, S, Amaria, R, Boasberg, P, Wallin, J, He, X, Cha, E, Richie, N, Ballinger, M, Smith, DC, Bauer, TM, Wasser, JS, Luke, JJ, Balmanoukian, AS, Kaufman, DR, Zhao, Y, Maleski, J, Leopold, L, Gangadhar, TC, Long, GV, Michielin, O, VanderWalde, A, Andtbacka, RHI, Cebon, J, Fernandez, E, Malvehy, J, Olszanski, AJ, Gause, C, Chen, L, Chou, J, Stephen Hodi, F, Brady, B, Mortier, L, Hassel, JC, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Lebbé, C, Ny, L, Chacon, M, Queirolo, P, Loquai, C, Cheema, P, Berrocal, A, Eizmendi, KM, Bar-Sela, G, Hardy, H, Weber, JS, Grob, J-J, Marquez-Rodas, I, Schmidt, H, Briscoe, K, Baurain, J-F, Wolchok, JD, Pinto, R, De Summa, S, Garrisi, VM, Strippoli, S, Azzariti, A, Guida, G, Guida, M, Tommasi, S, Jacquelot, N, Enot, D, Flament, C, Pitt, JM, Vimond, N, Blattner, C, Yamazaki, T, Roberti, M-P, Vetizou, M, Daillere, R, Poirier-Colame, V, la Semeraro, M, Caignard, A, Slingluff, CL, Sallusto, F, Rusakiewicz, S, Weide, B, Marabelle, A, Kohrt, H, Dalle, S, Cavalcanti, A, Kroemer, G, Di Giacomo, AM, Wong, P, Yuan, J, Umansky, V, Eggermont, A, Zitvogel, L, Anna, P, Marco, T, Stefania, S, Francesco, M, Mariaelena, C, Gabriele, M, Antonio, AP, Franco, S, Roberti, MP, Enot, DP, Semeraro, M, Jégou, S, Flores, C, Kwon, BS, Anderson, AC, Borg, C, Aubin, F, Ayyoub, M, De Presbiteris, AL, Cordaro, FG, Camerlingo, R, Fratangelo, F, Mozzillo, N, Pirozzi, G, Patriarca, EJ, Caputo, E, Motti, ML, Falcon, R, Miceli, R, Capone, M, Madonna, G, Mallardo, D, Carrier, MV, Panza, E, De Cicco, P, Armogida, C, Ercolano, G, Botti, G, Cirino, G, Sandru, A, Blank, M, Balatoni, T, Olasz, J, Farkas, E, Szollar, A, Savolt, A, Godeny, M, Csuka, O, Horvath, S, Eles, K, Shoenfeld, Y, Kasler, M, Costantini, S, Capone, F, Moradi, F, Berglund, P, Leandersson, K, Linnskog, R, Andersson, T, Prasad, CP, Nigro, CL, Lattanzio, L, Proby, C, Syed, N, Occelli, M, Cauchi, C, Merlano, M, Harwood, C, Thompson, A, Crook, T, Bifulco, K, Ingangi, V, Minopoli, M, Ragone, C, Pessi, A, Mannavola, F, D’Oronzo, S, Felici, C, Tucci, M, Doronzo, A, Silvestris, F, Ferretta, A, Guida, S, Maida, I, Cocco, T, Passarelli, A, Quaresmini, D, Franzese, O, Palermo, B, Di Donna, C, Sperduti, I, Foddai, M, Stabile, H, Gismondi, A, Santoni, A, Nisticò, P, Sponghini, AP, Platini, F, Marra, E, Rondonotti, D, Alabiso, O, Fierro, MT, Savoia, P, Stratica, F, Quaglino, P, Di Monta, G, Corrado, C, Di Marzo, M, Ugo, M, Di Cecilia, ML, Nicola, M, Fusciello, C, Marra, A, Guarrasi, R, Baldi, C, Russo, R, Di Giulio, G, Faiola, V, Zeppa, P, Pepe, S, Gambale, E, Carella, C, Di Paolo, A, De Tursi, M, Marra, L, De Murtas, F, Sorrentino, V, Voinea, S, Panaitescu, E, Bolovan, M, Stanciu, A, Cinca, S, Botti, C, Aquino, G, Anniciello, A, Fortes, C, Mastroeni, S, Caggiati, A, Passarelli, F, Zappalà, A, Capuano, M, Bono, R, Nudo, M, Marino, C, Michelozzi, P, De Biasio, V, Battarra, VC, Formenti, S, Ascierto, ML, McMiller, TL, Berger, AE, Danilova, L, Anders, RA, Netto, GJ, Xu, H, Pritchard, TS, Fan, J, Cheadle, C, Cope, L, Drake, CG, Pardoll, DM, Taube, JM, Topalian, SL, Gnjatic, S, Nataraj, S, Imai, N, Rahman, A, Jungbluth, AA, Pan, L, Venhaus, R, Park, A, Lehmann, FF, Lendvai, N, Cohen, AD, Cho, HJ, Daniel, S, and Hirsh, V

Abstract

MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunosc

Published
2016

23. Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients

Author

Sanmamed, M.F., primary, Perez-Gracia, J.L., additional, Fusco, J.P., additional, Oñate, C., additional, Perez, G., additional, Alfaro, C., additional, Martín-Algarra, S., additional, González, A., additional, Rodriguez-Ruiz, M.E., additional, Andueza, M.P., additional, Wang, J., additional, Bacchiocchi, A., additional, Halaban, R., additional, Kluger, H., additional, Sznol, M., additional, and Melero, I., additional

Published
2016
Full Text
View/download PDF

24. Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

Author

Sznol, M., primary, Ferrucci, P.F., additional, Hogg, D., additional, Atkins, M., additional, Wolter, P., additional, Guidoboni, M., additional, Lebbe, C., additional, Kirkwood, J., additional, Schachter, J., additional, Daniels, G., additional, Hassel, J., additional, Cebon, J., additional, Gerritsen, W., additional, Atkinson, V., additional, Thomas, L., additional, McCaffrey, J., additional, Power, D., additional, Jiang, J., additional, Hodi, F.S., additional, and Wolchok, J., additional

Published
2016
Full Text
View/download PDF

25. Combination immunotherapy: Where do we go from here?

Author

Overacre, AE, Kurtulus, S, Sznol, M, Pardoll, DM, Anderson, A, Vignali, DAA, Overacre, AE, Kurtulus, S, Sznol, M, Pardoll, DM, Anderson, A, and Vignali, DAA

Abstract

The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against "immunologically inert" tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.

Published
2015

27. Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Author

Gettinger, S.N., primary, Horn, L., additional, Gandhi, L., additional, Spigel, D.R., additional, Antonia, S.J., additional, Rizvi, N.A., additional, Powderly, J.D., additional, Heist, R.S., additional, Carvajal, R.D., additional, Jackman, D.M., additional, Sequist, L.V., additional, Smith, D.C., additional, Leming, P.D., additional, Topalian, S.L., additional, Hodi, F., additional, Sznol, M., additional, Harbison, C.T., additional, Kollia, G.D., additional, and Brahmer, J.R., additional

Published
2014
Full Text
View/download PDF

28. 1212TiP - PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

Author

Diab, A., Hurwitz, M.E., Tannir, N., Bernatchez, C., Haymaker, C., Bentebibel, S.E., Curti, B.D., Wong, M.K.K., Gergel, I., Tagliaferri, M., Zalevsky, J., Hoch, U., Aung, S., Imperiale, M., Cho, D., Tykodi, S.S., Puzanov, I., Kluger, H., Hwu, P., and Sznol, M.

Published
2017
Full Text
View/download PDF

30. Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel)

Author

Kluger, H., primary, Sznol, M., additional, Callahan, M., additional, Postow, M., additional, Gordon, R., additional, Segal, N.H., additional, Rizvi, N., additional, Lesokhin, A., additional, Atkins, M.B., additional, Kirkwood, J., additional, Burke, M., additional, Ralabate, A., additional, Rivera, A., additional, Kronenberg, S., additional, Agunwamba, B.U., additional, Feely, W., additional, Hong, Q., additional, Krishnan, S., additional, and Wolchok, J., additional

Published
2014
Full Text
View/download PDF

31. A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy

Author

Weber, J.S., primary, Minor, D.R., additional, D'Angelo, S.P., additional, Hodi, F.S., additional, Gutzmer, R., additional, Neyns, B., additional, Hoeller, C., additional, Khushalani, N.I., additional, Miller, W.H., additional, Grob, J-J., additional, Lao, C., additional, Linette, G., additional, Grossmann, K., additional, Hassel, J.C., additional, Lorigan, P., additional, Maio, M., additional, Sznol, M., additional, Lambert, A., additional, Yang, A., additional, and Larkin, J., additional

Published
2014
Full Text
View/download PDF

32. Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial

Author

McDermott, D.F., primary, Kluger, H., additional, Sznol, M., additional, Carvajal, R., additional, Lawrence, D., additional, Topalian, S.L., additional, Atkins, M.B., additional, Powderly, J.D., additional, Sharfman, W.H., additional, Puzanov, I., additional, Smith, D.C., additional, Leming, P.D., additional, Lipson, E., additional, Taube, J.M., additional, Anders, R.A., additional, Horak, C., additional, Kollia, G., additional, Sosman, J.A., additional, and Hodi, F.S., additional

Published
2014
Full Text
View/download PDF

33. Immune Correlates and Long Term Follow Up of a Phase Ia Study of Mpdl3280A, an Engineered Pd-L1 Antibody, in Patients with Metastatic Renal Cell Carcinoma (Mrcc)

Author

McDermott, D.F., primary, Sznol, M., additional, Sosman, J.A., additional, Soria, J-C., additional, Gordon, M.S., additional, Hamid, O., additional, Delord, J., additional, Fasso, M., additional, Wang, Y., additional, Bruey, J., additional, Fine, G., additional, and Powles, T., additional

Published
2014
Full Text
View/download PDF

34. Immunomodulatory Activity of Nivolumab in Previously Treated and Untreated Metastatic Renal Cell Carcinoma (Mrcc): Biomarker-Based Results from a Randomized Clinical Trial

Author

Choueiri, T., primary, Fishman, M.N., additional, Escudier, B., additional, Kim, J.J., additional, Kluger, H., additional, Stadler, W.M., additional, Perez-Garcia, J.L., additional, McNeel, D., additional, Curti, B., additional, Harrison, M.R., additional, Plimack, E.R., additional, Appleman, L., additional, Fong, L., additional, Drake, C.G., additional, Cohen, L., additional, Srivastava, S., additional, Jure-Kunkel, M., additional, Hong, Q., additional, Kurland, J., additional, and Sznol, M., additional

Published
2014
Full Text
View/download PDF

36. Future perspectives in melanoma research. Meeting report from the 'Melanoma Research: A bridge Naples-USA. Naples, December 6th-7 th2010'

Author

Ascierto, PA, De Maio, E, Bertuzzi, S, Palmieri, G, Halaban, R, Hendrix, M, Kashani-sabet, M, Ferrone, S, Wang, E, Cochran, A, Rivoltini, L, Lee, PP, Fox, BA, Kirkwood, JM, Ullmann, CD, Lehmann, FF, Sznol, M, Schwartzentruber, DJ, Maio, M, Flaherty, K, Galon, J, Ribas, A, Yang, J, Stroncek, DF, Mozzillo, N, Marincola, FM, Ascierto, PA, De Maio, E, Bertuzzi, S, Palmieri, G, Halaban, R, Hendrix, M, Kashani-sabet, M, Ferrone, S, Wang, E, Cochran, A, Rivoltini, L, Lee, PP, Fox, BA, Kirkwood, JM, Ullmann, CD, Lehmann, FF, Sznol, M, Schwartzentruber, DJ, Maio, M, Flaherty, K, Galon, J, Ribas, A, Yang, J, Stroncek, DF, Mozzillo, N, and Marincola, FM

Abstract

Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation. The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010. This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.© 2011 Ascierto et al; licensee BioMed Central Ltd.

Published
2011

39. Genome-wide screen of promoter methylation identifies novel markers in melanoma

Author

Koga, Y, Pelizzola, M, Cheng, E, Krauthammer, M, Sznol, M, Ariyan, S, Narayan, D, Molinaro, A, Halaban, R, Weissman, S, Molinaro, AM, Weissman, SM, Koga, Y, Pelizzola, M, Cheng, E, Krauthammer, M, Sznol, M, Ariyan, S, Narayan, D, Molinaro, A, Halaban, R, Weissman, S, Molinaro, AM, and Weissman, SM

Abstract

DNA methylation is an important component of epigenetic modifications, which influences the transcriptional machinery aberrant in many human diseases. In this study we present the first genome-wide integrative analysis of promoter methylation and gene expression for the identification of methylation markers in melanoma. Genome-wide promoter methylation and gene expression of eight early-passage human melanoma cell strains were compared with newborn and adult melanocytes. We used linear mixed effect models (LME) in combination with a series of filters based on the localization of promoter methylation relative to the transcription start site, overall promoter CpG content, and differential gene expression to discover DNA methylation markers. This approach identified 76 markers, of which 68 were hyper- and eight hypomethylated (LME, P < 0.05). Promoter methylation and differential gene expression of five markers (COL1A2, NPM2, HSPB6, DDIT4L, MT1G) were validated by sequencing of bisulfite-modified DNA and real-time reverse transcriptase PCR, respectively. Importantly, the incidence of promoter methylation of the validated markers increased moderately in early and significantly in advanced-stage melanomas, using early-passage cell strains and snap-frozen tissues (n = 18 and n = 24, respectively) compared with normal melanocytes and nevi (n = 11 and n = 9, respectively). Our approach allows robust identification of methylation markers that can be applied to other studies involving genome-wide promoter methylation. In conclusion, this study represents the first unbiased systematic effort to determine methylation markers in melanoma and revealed several novel genes regulated by promoter methylation that were not described in cancer cells before.

Published
2009

43. IMMUNOTHERAPY

Author

Hickey, M. J., primary, Malone, C. K., additional, Erickson, K. L., additional, Gerschenson, L. E., additional, Lin, A. H., additional, Inagaki, A., additional, Hiraoka, K., additional, Kasahara, N., additional, Mueller, B., additional, Kruse, C. A., additional, Kong, S., additional, Tyler, B., additional, Zhou, J., additional, Carter, B. S., additional, Brem, H., additional, Junghans, R. P., additional, Sampath, P., additional, Lai, R. K., additional, Recht, L. D., additional, Reardon, D. A., additional, Paleologos, N., additional, Groves, M., additional, Rosenfeld, M. R., additional, Davis, T., additional, Green, J., additional, Heimberger, A., additional, Sampson, J., additional, Hashimoto, N., additional, Tsuboi, A., additional, Chiba, Y., additional, Kijima, N., additional, Oka, Y., additional, Kinoshita, M., additional, Kagawa, N., additional, Fujimoto, Y., additional, Sugiyama, H., additional, Yoshimine, T., additional, Birks, S. M., additional, Burnet, M., additional, Pilkington, G. J., additional, Yu, J. S., additional, Wheeler, C. J., additional, Rudnick, J., additional, Mazer, M., additional, Wang, H. Q., additional, Nuno, M. A., additional, Richardson, J. E., additional, Fan, X., additional, Ji, J., additional, Chu, R. M., additional, Bender, J. G., additional, Hawkins, E. W., additional, Black, K. L., additional, Phuphanich, S., additional, Pollack, I. F., additional, Jakacki, R. I., additional, Butterfield, L. H., additional, Okada, H., additional, Hunt, M. A., additional, Pluhar, G. E., additional, Andersen, B. M., additional, Gallardo, J. L., additional, Seiler, C. O., additional, SantaCruz, K. S., additional, Ohlfest, J. R., additional, Bauer, D. F., additional, Lamb, L. S., additional, Harmon, D. K., additional, Zheng, X., additional, Romeo, A. K., additional, Gillespie, G. Y., additional, Parker, J. N., additional, Markert, J. M., additional, Jacobs, V. L., additional, Landry, R. P., additional, De Leo, J. A., additional, Bromberg, J. E., additional, Doorduijn, J., additional, Baars, J. W., additional, van Imhoff, G. W., additional, Enting, R., additional, van den Bent, M. J., additional, Murphy, K. A., additional, Bedi, J., additional, Epstein, A., additional, Olin, M., additional, Andersen, B., additional, Swier, L., additional, Ohlfest, J., additional, Litterman, A. J., additional, Zellmer, D. M., additional, Chiocca, E. A., additional, Aguilar, L. K., additional, Aguilar-Cordova, E., additional, Manzanera, A. G., additional, Harney, K. R., additional, Portnow, J., additional, Badie, B., additional, Lesniak, M., additional, Bell, S., additional, Ray-Chaudhuri, A., additional, Kaur, B., additional, Hardcastle, J., additional, Cavaliere, R., additional, McGregor, J., additional, Lo, S., additional, Chakarvarti, A., additional, Grecula, J., additional, Newton, H., additional, Trask, T. W., additional, Baskin, D. S., additional, New, P. Z., additional, Zeng, J., additional, See, A. P., additional, Phallen, J., additional, Belcaid, Z., additional, Durham, N., additional, Meyer, C., additional, Albesiano, E., additional, Pradilla, G., additional, Ford, E., additional, Hammers, H., additional, Tran, P. T., additional, Pardoll, D., additional, Drake, C. G., additional, Lim, M., additional, Ghazi, A., additional, Ashoori, A., additional, Hanley, P., additional, Salsman, V., additional, Schaffer, D. R., additional, Grada, Z., additional, Kew, Y., additional, Powell, S. Z., additional, Grossman, R., additional, Scheurer, M. E., additional, Leen, A. M., additional, Rooney, C. M., additional, Bollard, C. M., additional, Heslop, H. E., additional, Gottschalk, S., additional, Ahmed, N., additional, Hu, J., additional, Patil, C., additional, Nuno, M., additional, Wheeler, C., additional, Chu, R., additional, Black, K., additional, Yu, J., additional, Marabelle, A., additional, Kohrt, H., additional, Brody, J., additional, Luong, R., additional, Tse, V., additional, Levy, R., additional, Li, Y. M., additional, Jun, H., additional, Shahryar, M., additional, Daniel, V. A., additional, Walter, H. A., additional, Thaipisuttikul, I., additional, Avila, E., additional, Mitchell, D. A., additional, Archer, G. E., additional, Friedman, H. S., additional, Herndon, J. E., additional, Bigner, D. D., additional, Sampson, J. H., additional, Johnson, L. A., additional, Nair, S. K., additional, Schmittling, R., additional, Reap, E., additional, Knisely, J. P., additional, Kluger, H., additional, Flanigan, J., additional, Sznol, M., additional, Yu, J. B., additional, Chiang, V. L., additional, Prins, R. M., additional, Kim, W., additional, Soto, H., additional, Lisiero, D. N., additional, and Liau, L. M., additional

Published
2011
Full Text
View/download PDF

46. A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma

Author

Godshalk, S E, primary, Paranjape, T, additional, Nallur, S, additional, Speed, W, additional, Chan, E, additional, Molinaro, A M, additional, Bacchiocchi, A, additional, Hoyt, K, additional, Tworkoski, K, additional, Stern, D F, additional, Sznol, M, additional, Ariyan, S, additional, Lazova, R, additional, Halaban, R, additional, Kidd, K K, additional, Weidhaas, J B, additional, and Slack, F J, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results